Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
NL0015000LC2
Tue, 16.05.2023
Mainz BioMed N.V.
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
ColoAlert® Revenue Increases 152% Year Over Year
BERKELEY, US – MAINZ, Germany – May 16, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announce [ … ]
Tue, 16.05.2023
Mainz BioMed N.V.
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
ColoAlert® Revenue Increases 152% Year Over Year
BERKELEY, US – MAINZ, Germany – May 16, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announce [ … ]
Wed, 10.05.2023
Mainz BioMed N.V.
Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
Combination of DNA biomarkers with microbiome biomarkers has potential to enhance technical profile of novel pancreatic cancer screening test
Joint research project to discover disease specific microbiome biomarkers
BERKELEY, US and MAINZ, Germany – [May 10, 2023] [ … ]
Wed, 10.05.2023
Mainz BioMed N.V.
Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
Combination of DNA biomarkers with microbiome biomarkers has potential to enhance technical profile of novel pancreatic cancer screening test
Joint research project to discover disease specific microbiome biomarkers
BERKELEY, US and MAINZ, Germany – [May 10, 2023] [ … ]
Wed, 03.05.2023
Mainz BioMed N.V.
Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners
Eurofins GeLaMed to provide test kit processing of ColoAlert® through Germany.
BERKELEY, US – MAINZ, Germany – [May 3, 2023] — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the earl [ … ]
Wed, 03.05.2023
Mainz BioMed N.V.
Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners
Eurofins GeLaMed to provide test kit processing of ColoAlert® through Germany.
BERKELEY, US – MAINZ, Germany – [May 3, 2023] — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the earl [ … ]
Mon, 01.05.2023
Mainz BioMed N.V.
Mainz Biomed to Participate in Digestive Disease Week 2023
Largest international meeting of physicians, researchers, and academics covering gastroenterology, hepatology, endoscopy, and gastrointestinal surgery
BERKELEY, US – MAINZ, Germany – May 1, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diag [ … ]
Mon, 01.05.2023
Mainz BioMed N.V.
Mainz Biomed to Participate in Digestive Disease Week 2023
Largest international meeting of physicians, researchers, and academics covering gastroenterology, hepatology, endoscopy, and gastrointestinal surgery
BERKELEY, US – MAINZ, Germany – May 1, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diag [ … ]
Thu, 27.04.2023
Mainz BioMed N.V.
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
BERKELEY, US – MAINZ, Germany – April 27, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the following activi [ … ]
Thu, 27.04.2023
Mainz BioMed N.V.
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
BERKELEY, US – MAINZ, Germany – April 27, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the following activi [ … ]